65,437 trials
Neisseria Meningitidis
Primary: Estimate the Difference in Carriage Prevalence of Disease Associated Genogroups of N. Meningitidis (A, B, C, W, X, Y) Between School Leavers in 2018 (Year 12 in 2017)…
Metastatic Renal Cell Carcinoma
Primary: Number of Participants Categorized According to the Napping Habits for All Participants at Baseline — 22; 33; 31 Participants
Ovary Cancer · Cervix Cancer · Endometrium Cancer
Primary: Number of Participants Who Experienced a Treatment Emergent Adverse Event (TEAE) — 5 Participants
Vestibular Migraine · Migrainous Vertigo
Primary: Episodes With Vertigo Symptom Reduced From Moderate/Severe to None/Mild — 50; 73 Episodes — p=<0.33
Osteoarthritis, Knee
Primary: Compartment Specific Knee Minimum Joint Space Width (Varus - Medial Compartment, Valgus - Lateral Compartment) — 7.42; 3.92; 8.22; 7.47 mm
Craniotomy · Brain Surgery
Primary: Opioid Requirement After Surgery — 10; 4 Participants
Chronic Kidney Disease · Cardiovascular Disease · Metabolic Syndrome
Primary: Change is Leptin to Adiponectin Ratio (LAR) — 2.2; 1.3; 1.3; 1.4 ng/micrograms
Dizziness
Primary: Change in Static Subjective Visual Vertical (SVV) — 0.69; 0.58; 0.69; 0.89 degrees — p=0.97
Opioid Use · Postpartum Disorder · Chronic Pain Syndrome
Primary: Time to Opioid Cessation as a Measure of Opioid Utilization — 2; 2 weeks
Amyotrophic Lateral Sclerosis · Respiratory Muscle Weakness
Primary: Respiratory Complications Severity — 8.33; 9.0; 7.8 score on a scale
Metabolism · Protein
Primary: Whole Body Net Balance Measured by Gas Chromatography-Mass Spectrometry (GC-MS) — 14.58; 14.55 g protein per 300 mins
Ovulation Disorder · Ovarian Cysts
Primary: Number of Participants With Progesterone Level Greater Than 1.5 ng/mL — 9; 10 Participants
Atherosclerosis
Primary: Carotid Artery Stiffness (Expressed by Beta-stiffness Index ) in JAK2 V617F Positive ET Patients in Comparison to Healthy Control Subjects in a 4-year Period (From…
CHF · COPD
Primary: Pre-post Change in Combined Emergency and Urgent Care Service Utilization — 1.06; 1.03; 0.92; 0.71 care utilization events — p=0.45
Cutaneous Metastasis
Primary: Incidence of Treatment Emergent Adverse Events — 4; 3; 5; 10 Participants